Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice #
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and type 2 diabetes. The hyperinsulinemia that occurs as a consequence of insulin resistance is thought to be an important contributor to the development of fatty liver. We have shown that the iminosugar N-(5′-adamantane-1′-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM), an inhibitor of the enzyme glucosylceramide synthase, is a potent enhancer of insulin signaling in rodent models for insulin resistance and type 2 diabetes. The present study was designed to assess the impact of AMP-DNM on insulin levels, liver triglyceride synthesis, and gene expression profile. Treatment of ob/ob mice with AMP-DNM restored insulin signaling in the liver, corrected blood glucose values to levels found in lean mice, and decreased insulin concentration. The expression of sterol regulatory element-binding protein 1c target genes involved in fatty acid synthesis normalized. AMP-DNM treatment significantly reduced liver to body weight ratio and reversed hepatic steatosis, comprising fat as well as inflammatory markers. In addition, AMP-DNM treatment corrected to a large extent the gene expression profile of ob/ob mice livers toward the profile of lean mice. Conclusion: Pharmacological lowering of glycosphingolipids with the iminosugar AMP-DNM is a promising approach to restore insulin signaling and improve glucose homeostasis as well as hepatic steatosis. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Insulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191 · cited 1×
“This finding is of particular interest since inflammation is considered to be a contributing factor to the development of insulin resistance and obesity-related liver injury 31,32 .”
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Enhanced insulin sensitivity in mice lacking ganglioside GM3
Yamashita, T., Hashiramoto, A., Haluzik, M., Mizukami, H., Beck, S., Norton, A., Kono, M., Tsuji, S., Daniotti, J. L., Werth, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0635898100 · Cited by 531
(2004) · Seminars in Liver Disease · doi:10.1055/s-2004-823098 · Cited by 481
Adiponectin, Cardiovascular Function, and Hypertension
Wang, Z. V., & Scherer, P. E. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.099424 · Cited by 247
Kabayama, K. (2004) · Glycobiology · doi:10.1093/glycob/cwh135 · Cited by 155
Recent advances in nonalcholic fatty liver disease
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbccf2 · Cited by 94
Cited by
Ceramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616
A Ceramide-Centric View of Insulin Resistance
Chavez, J. A., & Summers, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.002 · Cited by 610
Stienstra, R., Saudale, F., Duval, C., Keshtkar, S., Groener, J. E. M., van Rooijen, N., Staels, B., Kersten, S., & Müller, M. (2010) · Hepatology · doi:10.1002/hep.23337 · Cited by 452
Ceramides as modulators of cellular and whole-body metabolism
Bikman, B. T., & Summers, S. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57144 · Cited by 419
Ceramides in Metabolism: Key Lipotoxic Players
Chaurasia, B., & Summers, S. A. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-093815 · Cited by 343
Metadata
- Authors
- Bijl, N., Sokolović, M., Vrins, C., Langeveld, M., Moerland, P. D., Ottenhoff, R., van Roomen, C. P. A. A., Claessen, N., Boot, R. G., Aten, J., Groen, A. K., Aerts, J. M. F. G., & van Eijk, M.
- Venue
- Hepatology
- Published
- 2009-11
- Volume
- 50
- Issue
- 5
- Pages
- 1431-1441
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1968572179
- Cited by
- 92
- References
- 8
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice #. https://app.cochat.ai/papers/10.1002/hep.23175
- The paper
- Bijl, N., Sokolović, M., Vrins, C., Langeveld, M., Moerland, P. D., Ottenhoff, R., van Roomen, C. P. A. A., Claessen, N., Boot, R. G., Aten, J., Groen, A. K., Aerts, J. M. F. G., & van Eijk, M. (2009). Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice #. Hepatology. https://doi.org/10.1002/hep.23175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.